Cliftonlarsonallen Wealth Advisors LLC Makes New $2.95 Million Investment in Danaher Corporation $DHR

Key Points

• Cliftonlarsonallen Wealth Advisors acquired 13,330 Danaher shares worth approximately $2.95 million during the third quarter, while institutional investors collectively own 79.05% of the company.
• Danaher recently exceeded quarterly expectations, reporting $1.94 in adjusted earnings per share and $6.26 billion in revenue, with revenue up 5.5% year over year.
• The company’s collaboration with NVIDIA on AI-powered autonomous science is viewed as a potential long-term growth catalyst; analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $235.41 price target.

Cliftonlarsonallen Wealth Advisors LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,330 shares of the conglomerate's stock, valued at approximately $2,953,000.

Several other hedge funds and other institutional investors also recently modified their holdings of DHR. Marquette Asset Management LLC raised its stake in shares of Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 73 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new stake in Danaher during the second quarter valued at approximately $25,000. Main Street Group LTD acquired a new stake in Danaher during the first quarter valued at approximately $25,000. Field & Main Bank acquired a new stake in Danaher during the second quarter valued at approximately $29,000. Finally, Evolution Wealth Management Inc. lifted its holdings in Danaher by 208.0% during the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock worth $29,000 after buying an additional 104 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Price Performance

Shares of DHR opened at $224.65 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market cap of $157.93 billion, a P/E ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The stock has a fifty day moving average price of $212.92 and a 200 day moving average price of $195.39.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 earnings per share. On average, research analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher's payout ratio is currently 28.42%.

Analysts Set New Price Targets

DHR has been the subject of several research reports. Stifel Nicolaus decreased their target price on Danaher from $260.00 to $220.00 and set a "buy" rating for the company in a research report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft restated a "buy" rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Royal Bank Of Canada lifted their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an "outperform" rating in a report on Monday, October 5th. Morgan Stanley lifted their price objective on shares of Danaher from $220.00 to $240.00 and gave the stock an "overweight" rating in a report on Monday. Finally, Weiss Ratings raised shares of Danaher from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $235.41.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.